The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Relationship of Lipoproteins to Cardiovascular Events
Open accessAbstract
Objectives This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. Background During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)-lowering therapy did not reduce CV events compared with LDL-C-lowering therapy alone. Methods Subjects taking simvastatin and/or ezetimibe were randomized to receive extended-release (ER) niacin 1,500 to 2,000 mg or minimal immediate-release niacin (≤ 150 mg) as placebo at bedtime. LDL-C levels in both groups were maintained from 40 to 80 mg/dl. Hazard ratios were estimated by using Cox proportional hazards models for relationships between lipoproteins and the composite endpoint of CV death, myocardial infarction, acute coronary syndrome, ischemic stroke, or symptom-driven revascularization. Results CV outcomes were not associated with ER niacin in any baseline lipoprotein tertile. In a subset of patients in both the highest triglyceride (≥ 198 mg/dl) and lowest HDL-C (<33 mg/dl) tertiles, ER niacin showed a trend toward benefit (hazard ratio: 0.74, p = 0.073). In-trial LDL-C levels, non-HDL-C levels, and the total cholesterol/HDL-C ratio were positively associated with CV events in the control group, but these relationships were absent in the ER niacin group. Conclusions Baseline lipoprotein tertiles did not predict differential benefit or harm with ER niacin added to LDL-C-lowering therapy, but a small dyslipidemic subgroup may benefit. ER niacin attenuated expected relationships of lipoprotein risk factors with CV events, raising the possibility that nonlipoprotein actions of niacin could affect risk. (Niacin Plus Statin to Prevent Vascular Events [AIM-HIGH]; NCT00120289).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“subgroup analyses suggested possible benefits to TG lowering in patients with dyslipidemia.5, 6”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, any benefits to TG‐lowering therapies may be most pronounced among statin‐treated patients in the higher range of TG elevation (ie, ≥200 mg/dL),4, 5, 6 for whom randomized prospectively designed outcome studies have not been previously conducted prior to the REDUCE‐IT study.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“The subgroup data (Table 5) from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid,6 Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM‐HIGH),5 and JELIS4 trials further support a prospective study of EPA in a broader patient population with hypertriglyceridemia, as exemplified in REDUCE‐IT, as a potent”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
IX. On the problem of the most efficient tests of statistical hypotheses
Neyman, J., & Pearson, E. S. (1933) · Philosophical Transactions of the Royal Society of London Series A Containing Papers of a Mathematical or Physical Character · doi:10.1098/rsta.1933.0009 · Cited by 2,370
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
ON THE PROBLEM OF THE MOST EFFICIENT TESTS OF STATISTICAL HYPOTHESES
Neyman, J., & Pearson, E. S. (1967) · University of California Press eBooks · doi:10.1525/9780520339897-008 · Cited by 1,545
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
Carlson, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 591
Cited by
Sorted by citations
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
Michos, E. D., McEvoy, J. W., & Blumenthal, R. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806939 · Cited by 354
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
Self-citationThe Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
Niacin for primary and secondary prevention of cardiovascular events
Schandelmaier, S., Briel, M., Saccilotto, R. T., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009744.pub2 · Cited by 120
Toth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008740 · Cited by 117
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 119
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00470 · Cited by 102
Albers, J. J., Slee, A. E., Fleg, J. L., O’Brien, K. D., & Marcovina, S. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.019 · Cited by 95
Self-citationHDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease
Kontush, A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.005 · Cited by 93
Diagnosis and treatment of high density lipoprotein deficiency
Schaefer, E. J., Anthanont, P., Diffenderfer, M. R., Polisecki, E. Y., & Asztalos, B. F. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.006 · Cited by 89
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 81
Self-citationBeyond Coronary Calcification, Family History, and C-Reactive Protein
Mody, P. S., Joshi, P. H., Khera, A., Ayers, C. R., & Rohatgi, A. K. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.538 · Cited by 76
Budoff, M. J., Muhlestein, J. B., Le, V. T., May, H. T., Roy, S. K., & Nelson, J. R. (2018) · Clinical Cardiology · doi:10.1002/clc.22856 · Cited by 73
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Kalil, R. S., Wang, J., de Boer, I. H., Mathew, R. O., Ix, J. H., Asif, A., Shi, X., & Boden, W. E. (2015) · Kidney International · doi:10.1038/ki.2014.383 · Cited by 66
Self-citationMaki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Self-citationNew Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 62
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57
Fan, W., Philip, S., Granowitz, C. B., Toth, P. P., & Wong, N. D. (2019) · Diabetes Care · doi:10.2337/dc19-0501 · Cited by 58
2013 ACC/AHA Cholesterol Treatment Guideline
Martin, S. S., Abd, T. T., Jones, S. R., Michos, E. D., Blumenthal, R. S., & Blaha, M. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.578 · Cited by 56
Ooi, E. M. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P. A., Marcovina, S. M., & Barrett, P. H. R. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306136 · Cited by 54
Self-citationToth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 59
Time to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 51
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 52
Rana, J. S., Liu, J. Y., Moffet, H. H., Solomon, M. D., Go, A. S., Jaffe, M. G., & Karter, A. J. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.039 · Cited by 50
Wang, K., Wang, R., Yang, J., Liu, X., Shen, H., Sun, Y., Zhou, Y., Fang, Z. A., & Ge, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913869 · Cited by 49
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 48
Niacin and heart disease prevention: Engraving its tombstone is a mistake
Superko, H. R., Zhao, X.-Q., Hodis, H. N., & Guyton, J. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.005 · Cited by 47
Self-citationSaturated Fat: Part of a Healthy Diet
Gershuni, V. M. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0238-x · Cited by 48
Martin, S. S., & Blumenthal, R. S. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2805 · Cited by 46
Rahman, K., & Fisher, E. A. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00032 · Cited by 48
Niacin as antidyslipidemic drug
Julius, U. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0478 · Cited by 43
Statins for primary prevention of venous thromboembolism
Li, L., Zhang, P., Tian, J. H., & Yang, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub3 · Cited by 42
HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome
Alcover, S., Ramos-Regalado, L., Girón, G., Muñoz‐García, N., & Vilahur, G. (2025) · Antioxidants · doi:10.3390/antiox14040434 · Cited by 50
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 42
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Streja, E., Kovesdy, C. P., Streja, D. A., Moradi, H., Kalantar‐Zadeh, K., & Kashyap, M. L. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.033 · Cited by 39
Self-citationManaging Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 38
Pleiotropic effects of niacin: Current possibilities for its clinical use
Zeman, M., Vecka, M., Perlík, F., Staňková, B., Hromádka, R., TVRZICKÁ, E., Širc, J., Hrib, J., & Žák, A. (2016) · Acta Pharmaceutica · doi:10.1515/acph-2016-0043 · Cited by 37
Gao, M., Yang, C., Wang, X., Guo, M., Liu, Y., Gao, S., Zhang, X., Ruan, G., Li, X., Tian, W., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154296 · Cited by 36
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Sesamol Reduces the Atherogenicity of Electronegative L5 LDL in Vivo and in Vitro
Chen, W., Chen, F.-Y., Lee, A., Ting, K.-H., Chang, C., Hsu, J., Lee, W.-S., Sheu, J., Chen, C., & Shen, M. (2015) · Journal of Natural Products · doi:10.1021/np500700z · Cited by 35
Pang, J., Chan, D. C., Hamilton, S. J., Tenneti, V. S., Watts, G. F., & Barrett, P. H. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302019 · Cited by 34
Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 45
Biomarker-Guided Dietary Supplementation: A Narrative Review of Precision in Personalized Nutrition
Pokushalov, E., Ponomarenko, A., Shrainer, E., Kudlay, D. A., & Miller, R. (2024) · Nutrients · doi:10.3390/nu16234033 · Cited by 39
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Liu, X., Tao, L., Cao, K., Wang, Z., Chen, D., Guo, J. C., Zhu, H., Yang, X., Wang, Y., Wang, J., et al. (2015) · BMC Public Health · doi:10.1186/s12889-015-1747-9 · Cited by 33
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
Toth, P. P., Shah, P. K., & Lepor, N. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100086 · Cited by 35
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
O’Brien, K. D., Hippe, D. S., Chen, H., Neradilek, M. B., Probstfield, J. L., Peck, S., Isquith, D. A., Cantón, G., Yuan, C., Polissar, N. L., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.032 · Cited by 29
Self-citationThe Remnants of Residual Risk∗
Joshi, P. H., Martin, S. S., & Blumenthal, R. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.543 · Cited by 29
Niacin decreases leukocyte myeloperoxidase: Mechanistic role of redox agents and Src/p38MAP kinase
Ganji, S. H., Kamanna, V. S., & Kashyap, M. L. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.948 · Cited by 28
Self-citationCan pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson, J. R., True, W. S., Le, V., & Mason, R. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1385365 · Cited by 27
Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum
Harman, S. M. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.042 · Cited by 27
Zambon, A., Zhao, X.-Q., Brown, B. G., & Brunzell, J. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.426 · Cited by 26
Self-citationGenetics of Dyslipidemia and Ischemic Heart Disease
Sharma, K., & Baliga, R. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0855-9 · Cited by 26
Wang, F., Ye, P., Hu, D., Min, Y., Zhao, S., Wang, Y., Mu, Y., Yan, X., Li, Z., Wei, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.023 · Cited by 26
Kosugi, T., Eriguchi, M., Yoshida, H., Tasaki, H., Fukata, F., Nishimoto, M., Matsui, M., Samejima, K., Iseki, K., Fujimoto, S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.004 · Cited by 28
High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases
Ikenaga, M., Higaki, Y., Saku, K., & Uehara, Y. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33720 · Cited by 24
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 24
Khoury, P. E., Waldmann, E., Huby, T., Gall, J., Couvert, P., Lacorte, J., Chapman, J., Frisdal, É., Lesnik, P., Parhofer, K. G., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306834 · Cited by 23
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 25
Kroon, T., Baccega, T., Olsén, A., Gabrielsson, J., & Oakes, N. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m068395 · Cited by 23
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 23
Self-citationDing, R., He, Z., Lin, Z., Wu, F., Zhang, F., Jiayou, Z., Yusheng, R., Min, F., Chun, L., & Wu, Z. (2015) · Apmis · doi:10.1111/apm.12362 · Cited by 22
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Cardiorenal Medicine · doi:10.1159/000502511 · Cited by 22
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 22
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 22
Jin, J., Zhang, H., Cao, Y., Liu, H., Hua, Q., Li, Y., Zhang, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01125-1 · Cited by 20
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 21
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 17
Mitsis, A., Kyriakou, M., Sokratous, S., Karmioti, G., Drakomathioulakis, M., Myrianthefs, M. M., Ziakas, A., Tzikas, S., & Kassimis, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030701 · Cited by 18
Hagström, E., Roe, M. T., Hafley, G. E., Neely, M. L., Sidhu, M. S., Winters, K. J., Prabhakaran, D., White, H. D., Armstrong, P. W., Fox, K. A. A., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22533 · Cited by 16
Self-citationStatin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
Jin, C., O'Boyle, S., Kleven, D. T., Pollock, J. S., Pollock, D. M., & White, J. J. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12250 · Cited by 15
Functionality of High-Density Lipoprotein as Antiatherosclerotic Therapeutic Target
Hoekstra, M., & van Berkel, T. J. C. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308262 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia
Kim, E. S., & McCormack, P. L. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0099-7 · Cited by 14
Davidson, M. H., Phillips, A., Kling, D. F., & Maki, K. C. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.942640 · Cited by 14
Is HPS2-THRIVE the death knell for niacin?
Toth, P. P., Murthy, A., Sidhu, M. S., & Boden, W. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.008 · Cited by 13
Self-citationCase, B. C., Bress, A. P., Kolm, P., Philip, S., Herrick, J. S., Granowitz, C. B., Toth, P. P., Fan, W., Wong, N. D., HULL, M. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.004 · Cited by 13
Self-citationManagement of Hyperlipidemia After Stroke
Brooks, D. C., & Schindler, J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0774-8 · Cited by 13
A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 13
Pang, J., Chan, D. C., Hamilton, S. J., Tenneti, V. S., Watts, G. F., & Barrett, P. H. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12622 · Cited by 12
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
Benes, L. B., Bassi, N. S., & Davidson, M. H. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s58149 · Cited by 12
Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
Dunbar, R. L., & Goel, H. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0563-8 · Cited by 11
Metadata
- Authors
- Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., Xu, P., Zhao, X.-Q., & Boden, W. E.
- Affiliations
- Duke University (US)
- University of Calgary (CA)
- National Heart, Lung, and Blood Institute (US)
- University of Miami (US)
- University of California, Irvine (US)
- University of Washington (US)
- SUNY Upstate Medical University (US)
- Albany Stratton VA Medical Center Albany (US)
- Corresponding author
- Guyton, John R.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 17
- Pages
- 1580-1584
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC3862446
- OpenAlex
- W2189339462
- Cited by
- 182
- References
- 23
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 15 · 2019: 16 · 2018: 12 · 2017: 15 · 2016: 28 · 2015: 33 · 2014: 22 · 2013: 3
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01-HL-081616, U01-HL-081649)
- Abbott Laboratories
- Merck & Co.
- Regeneron
- Sanofi US
- Genzyme Corporation, Isis Pharmaceuticals
- Amgen
- Amarin
- GlaxoSmithKline
- Merck
- Roche
- Abbott
- AstraZeneca
- Eli Lilly
- Sanofi
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nicotinic acid, lipoproteins, cardiovascular events, AIM-HIGH trial, extended-release niacin, low HDL cholesterol, triglycerides, LDL-C lowering therapy, simvastatin, ezetimibe, non-HDL cholesterol, TC/HDL-C ratio, cardiovascular risk prediction
- MeSH terms
- Aged, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Niacin, Prospective Studies, Triglycerides, Global Health, Biomarkers, Treatment Outcome, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
